# i&i Prague

> i&i Prague is a VC fund backing Biotechnology, Medical and Life Science. See 15 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 15
- Last investment: Jan 2026
- Lead investor: 40%
- Last updated: Aug 2026

i&i Prague is a VC fund focused on Biotechnology and Medical. A biotech incubator

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 7 | 47% |
| Medical | 6 | 40% |
| Life Science | 5 | 33% |
| Health Care | 3 | 20% |
| Nanotechnology | 3 | 20% |

15 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 9 | 60% |
| Series A | 2 | 13% |
| Pre-Seed | 1 | 7% |
| Non-equity Assistance | 1 | 7% |
| Venture - Series Unknown | 1 | 7% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Czech Republic | 6 | 40% |
| United States | 2 | 13% |
| France | 1 | 7% |
| Austria | 1 | 7% |
| Germany | 1 | 7% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Adalid Sciences | Adalid Sciences specializes in advanced drug delivery systems for genomic medicine, utilizing innovative lipid nanoparticles. |  | Pre-Seed | Jan 01, 2026 |  |
| Nanoflexion | Nanoflexion is a life sciences company that develops a sterile nanofiber patch to facilitate the healing of gastrointestinal anastomosis. |  | Non-equity Assistance | Oct 01, 2025 |  |
| Casinvent Pharma | Casinvent Pharma develops new therapeutic options for the treatment of selected malignancies. |  | Venture - Series Unknown | Jul 02, 2025 |  |
| PerioTrap Pharmaceuticals GmbH | PerioTrap is an early stage biopharmaceutical company that aims to eradicate the root cause of periodontitis | $3M | Seed | Jan 30, 2025 |  |
| Deep MedChem | Deep MedChem is the operator of artificial intelligence based tools intended for drug development and medicinal chemistry. |  | Seed | Jan 01, 2025 |  |
| Casinvent Pharma | Casinvent Pharma develops new therapeutic options for the treatment of selected malignancies. | $1.7M | Seed | Jan 30, 2024 |  |
| Sophomer | Sophomer provides artificial polymers made to replace the bovine serum albumin that is used in immunological tests. | $368.7K | Seed | Mar 29, 2023 |  |
| Sampling Human | The mission of Sampling Human is to couple health related decisions to their effects at the single cell level. It is inspired by the founders’ academic and professional efforts to extend what is measurable and to derive what must be measured.The human body is a complex system that cannot be quantified exhaustively or heuristically. Clinicaldiagnosis today is an imprecise art. On average, diagnosis of rare diseases is 5 years delayed with 50% of delays impacting the outcome. Misdiagnosis is far too common with a 66% likelihood of disagreement between experts. We are stuck with symptoms based medicine.The nature of physiological data is to blame. Decisions today are based on fuzzy variables (tired, drowsy, weak, tingling, itchy, etc). Better decisions will require precise knowledge regarding the fundamental physiological units of our bodies, CELLS. | $2M | Seed | Apr 12, 2022 |  |
| Celeris Therapeutics | Celeris Therapeutics is a deep learning company that uses innovative, computer-based methods to degrade undruggable targets. The platform Celeris One exploits the potential of degrader technologies with accurate predictions of biomolecular interactions and the expansion of chemical space.Celeris One uses methods such as Graph RepresentationLearning, Active Learning, Data Augmentation, and Generative Models to expand the chemical space and leverage sparse and heterogeneous data. This leads to the design of Heterobifunctional and Glue Degraders, as well as Small Molecules. | $3.4M | Seed | Feb 10, 2022 |  |
| PEP-Therapy | PEP-Therapy is a biotechnology company developing first-in-class peptides as targeted therapies for severe diseases, with an initial focus on cancer. PEP-Therapy develops Cell Penetrating and Interfering Peptides (CP&IP) for the intracellular delivery of targeted therapies. These active compounds penetrate cells and block relevantintracellular protein-protein interactions, thus inhibiting key pathological mechanisms. | $1.9M | Series A | Jul 19, 2021 |  |

10 of 15 investments shown.

## Co-investors
- [KHAN Technology Transfer Fund](https://shizune.co/investors/profile/khan-technology-transfer-fund) — VC Fund, 4 deals together
- [bmp Ventures](https://shizune.co/investors/profile/bmp-ag) — VC Fund, 3 deals together
- [i&i Biotech Fund](https://shizune.co/investors/profile/i-i-biotech-fund) — VC Fund, 3 deals together
- [Anaxago](https://shizune.co/investors/profile/anaxago) — VC Fund, 2 deals together
- [Holecek Family Foundation](https://shizune.co/investors/profile/hole%C4%8Dek-family-foundation) — VC Fund, 2 deals together
- [Longevitytech.fund](https://shizune.co/investors/profile/longevitytech-fund) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does i&i Prague invest in?

i&i Prague invests primarily in Biotechnology, Medical and Life Science startups, most often at Seed and Series A stage. Most of the 15 investments tracked by Shizune back companies in Czech Republic. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did i&i Prague last invest?

The most recent investment recorded for i&i Prague closed in Jan 2026. Shizune tracks 15 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co